Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CBIO vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: CBIO 2 – 3 LCTX (1 Tie) Matrix Metrics: CBIO 4 – 6 LCTX

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CBIO carries a Unified Composite Score of 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. CBIO 49.2/100 HOLD) and 1.39β · 79% Vol risk profile, whereas CBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CBIO vs LCTX
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap $539.5M
TTM Revenue $15M
Forward P/E N/M
Beta / 30D Vol 1.18β · 60% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.1 · SMA20: $13.45 · SMA50: $14.10
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (CBIO 2 – 3 LCTX)

Columns: Metric · CBIO · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue 24.6x 15.9x
2. Growth & Scale CBIO
Revenue Growth (YoY) +0.0% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $15M $11M
Market Cap $539.5M $207.4M
3. Profitability & Quality LCTX
Gross Margin 100.0% -95.0%
Operating Margin -1228.4% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -160.8% 4.3%
4. Balance Sheet & Cash Flow CBIO
Cash Generation (TTM) -$154M -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $170M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LCTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 215.9% (98th %ile) 0.0% (<1st %ile)
Put/Call OI Skew 1.00x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CBIO (4) vs LCTX (6)
Institutional Metric CBIO LCTX Criterion Row Edge
Market Capitalization
Scale
$539.5M $207.4M Larger Scale CBIO
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
+0.0% -61.0% Higher Growth CBIO
Operating Margin (TTM)
Profitability
-1228.4% -280.3% Higher Margin LCTX
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-160.8% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
23% ($9–$27) 0% ($1–$2) Stronger Trend CBIO
Beta / 30D Volatility
Risk Regime
1.18β · 60% Vol 1.39β · 79% Vol Lower Realized Risk CBIO
Unified Institutional Score
Composite Signal
49.2 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$15M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 24.6x EV/Rev 10.64x PEG · 15.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$154M ($170M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CBIO +20.56 pp
CBIO: -1.07% · LCTX: -21.63%
3M Horizon CBIO +5.79 pp
CBIO: -23.39% · LCTX: -29.18%
6M Horizon CBIO +3.3 pp
CBIO: -37.32% · LCTX: -40.62%
1Y Horizon CBIO +54.63 pp
CBIO: -0.23% · LCTX: -54.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CBIO Revenue LCTX Revenue CBIO Op. Margin LCTX Op. Margin Margin Leader
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 $10M $0M -506.8% -1448.4% CBIO
FY2021 $0M $0M -5470.7% -1133.6% LCTX
FY2022 $0M $10M -63204.4% -153.2% LCTX
FY2023 $0M $10M -392752.9% -276.5% LCTX
FY2024 N/A $10M N/A -226.1% LCTX
FY2025 $10M $10M -1407.5% -251.6% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CBIO BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 215.9%
IV Percentile 98th %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $539.5M market capitalization and -1228.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CBIO vs LCTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CBIO carries a Unified Composite Score of 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin), whereas LCTX carries 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. CBIO 49.2/100 HOLD) and 1.39β · 79% Vol risk profile, whereas CBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CBIO leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CBIO cumulative revenue shifted +0.0% while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 24.6x EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CBIO carries 215.9% implied volatility (98th %ile, Extreme (>80th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 60% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.